Literature DB >> 50744

Factors responsible for ADP-induced release reaction of human platelets.

J F Mustard, D W Perry, R L Kinlough-Rathbone, M A Packham.   

Abstract

Extensive aggregation of human platelets can be induced by ADP without secondaryaggregation or release of granule contents. This occurs with washed platelets in Tyrode solution containing 0.35% albumin, human fibrinogen, and apyrase, and in platelet-rich, heparin- or hirudin-plasma. Conditions that caused release during ADP-inducedaggregation were-citrate as the anticoagulant in platelet-rich plasma; addition of citrate (11-15 mM) to a suspension of washed platelets, or to hirudin-plasma or heparin-plasma; suspension of platelets in a medium containing magnesium but no calcium;and the presence of trace amounts of thrombin or aggregated gamma globulin in the platelet suspensions. Acetylsalicylic acid, phenylbutazone, or sulfinpyrazone inhibited secondary aggregation and release in all these circumstances. Heparin or hirudin inhibited ADP-INDUCED SECONDARY AGGREGATION AND RELEASE PROMOTED BY TRACES OF THROMBIN. Although fibrinogen is required for ADP-induced primary aggregation, it does not support secondary aggregation and release, provided that it has no clot-promoting activity. The main agent responsible for ADP-induced secondary aggregation and release in human, citrated, platelet-rich plasma appears to be sodium citrate. Suspending washed human platelets in a medium without calcium mimics the effect of citrate.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 50744     DOI: 10.1152/ajplegacy.1975.228.6.1757

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  44 in total

Review 1.  P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells.

Authors:  Christian Gachet
Journal:  Purinergic Signal       Date:  2012-04-11       Impact factor: 3.765

Review 2.  Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact?

Authors:  Diana A Gorog; Joseph M Sweeny; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2009-04-14       Impact factor: 32.419

3.  Divalent cation regulation of the surface orientation of platelet membrane glycoprotein IIb. Correlation with fibrinogen binding function and definition of a novel variant of Glanzmann's thrombasthenia.

Authors:  M H Ginsberg; A Lightsey; T J Kunicki; A Kaufmann; G Marguerie; E F Plow
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

4.  Historical perspective on ADP-induced platelet activation.

Authors:  Marian A Packham; Margaret L Rand
Journal:  Purinergic Signal       Date:  2011-04-02       Impact factor: 3.765

5.  Molecular defects of the platelet P2 receptors.

Authors:  Marco Cattaneo
Journal:  Purinergic Signal       Date:  2011-01-29       Impact factor: 3.765

6.  Immunoglobulin G is a platelet alpha granule-secreted protein.

Authors:  J N George; S Saucerman; S P Levine; L K Knieriem; D F Bainton
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

7.  Arachidonate metabolism, 5-hydroxytryptamine release and aggregation in human platelets activated by palmitaldehyde acetal phosphatidic acid.

Authors:  J P Brammer; M H Maguire
Journal:  Br J Pharmacol       Date:  1984-05       Impact factor: 8.739

Review 8.  Characteristics of an ADP receptor mediating platelet activation.

Authors:  R W Colman; W R Figures
Journal:  Mol Cell Biochem       Date:  1984       Impact factor: 3.396

9.  Gel-filtered human platelets. Ultrastructure, function, and role of proteins in inhibition of aggregation by aspirin.

Authors:  K M Fine; P C Ashbrook; L P Brigden; J E Maldonado; P Didishelm
Journal:  Am J Pathol       Date:  1976-07       Impact factor: 4.307

10.  Human recombinant interleukin-1 beta induces thromboxane A2 release in polymorphonuclear leukocytes, macrophages and platelets: effect of IL-1 receptor antagonist.

Authors:  M Reale; R C Barbacane; S Frydas; G Anogianakis; A Trakatellis; D Dimitriadou; D Vacalis; F C Placido; P De Fazio; E Porreca; C Di Febbo; P Conti
Journal:  Mol Cell Biochem       Date:  1996-06-21       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.